Navigation Links
Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
Date:5/23/2017

Vortex Biosciences, provider of circulating tumor cell (CTC) capture systems, today announced the publication of “Label-free isolation of prostate circulating tumor cells using Vortex microfluidic technology” in Nature Precision Oncology on May 8th. The peer reviewed publication is the result of a collaboration with Dr. Dino Di Carlo and Dr. Matthew Rettig at the University of California, Los Angeles. The publication describes the use of Vortex technology for the isolation and characterization of CTCs from 22 patients with advanced prostate cancer. CTCs can provide both genetic and phenotypic information about tumor evolution, potentially from both primary and metastatic sites. In this paper, the utility of the Vortex technology to support the capture and characterization of CTCs from prostate cancer patients was demonstrated.

The Vortex technology isolates and collects CTCs directly from whole blood based on the greater deformability and larger size of the cells. CTCs are collected unbiased by their molecular characteristics and available for a wide range of analysis, providing a window into a patient’s cancer biology. The paper describes the capturing of CTCs from prostate cancer patients with high purity (from 1.74 to 37.59%) and efficiency (from 1.88 to 93.75 CTCs/7.5mL). Interestingly, atypical large circulating cells were identified in 5 age-matched healthy donors (46-77 years old; 1.25-2.5 CTCs/7.5 mL) but not in 5 healthy donors <30 years-old (21-27 years old; 0.00 CTC/7.5 mL). Using a threshold calculated from the 5 age-matched healthy donors (3.37 CTCs/mL), CTCs were identified at levels above the healthy threshold in 80% of the prostate cancer patients. A fraction of the cells collected (11.5%) did not express epithelial prostate markers (CK and/or PSA) and some instead expressed markers of epithelial-mesenchymal transition (EMT), i.e. vimentin and N-cadherin.

"We are excited to see how effective the Vortex technology is for isolating CTCs independent of their epithelial properties, making them available for both genomic and phenotypic analysis,“ said Dr. Dino Di Carlo, Director of the Microfluidic Biotechnology Laboratory at UCLA and Director of the Cancer Nanotechnology Program of the Jonsson Comprehensive Cancer Center. "The work demonstrated in this paper shows what a powerful window into patient cancer biology CTCs can be with the right collection system."

The fully automated VTX-1 Liquid Biopsy System from Vortex represents the next step in CTC isolation. The Vortex system utilizes a proprietary microfluidic chip to stably trap and capture CTCs in micro-scale vortices based on their larger size and greater deformability than the white and red blood cells. With excellent CTC recovery, best in class CTC purity, and collected CTCs being viable, and ready for downstream analysis, the VTX-1 offers the best CTC samples available today.

About Vortex Biosciences
Vortex Biosciences is a cancer research and diagnostics company that integrates cancer biology, microfluidic engineering and informatics to develop tools for isolating and characterizing circulating tumor cells. The Vortex VTX-1 instrument harvests intact circulating tumor cells from whole blood samples for use in downstream research and clinical applications such as patient stratification in clinical trials, monitoring disease progression and drug treatment effectiveness. With a mission to enable noninvasive diagnosis of cancer and real-time monitoring throughout a patient’s treatment, Vortex is at the forefront of accelerating cancer research and improving patient outcomes. Vortex is a core subsidiary of NetScientific plc, a transatlantic healthcare technology group with an investment strategy focused on sourcing, funding and commercializing technologies that significantly improve the health and well-being of people with chronic diseases. For more information, visit http://www.vortexbiosciences.com.

Read the full story at http://www.prweb.com/releases/2017/05/prweb14354838.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related biology technology :

1. Vortex Biosciences Presents Studies at AACR That Demonstrate Use of the VTX-1 System for Isolating and Analyzing Circulating Tumor Cells for Cancer Research
2. Vortex Biosciences Announces Commercial Launch of Fully Automated System for CTC Isolation
3. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
4. Vortex Biosciences Appoints Dr. Massimo Cristofanilli As Chairman of Newly Formed Scientific Advisory Board
5. Vortex Biosciences Inventor Receives Presidential Award for Research Leading to Groundbreaking "Liquid Biopsy" Technique
6. Therapix Biosciences Announces the Appointment of Josh Blacher as Chief Financial Officer
7. ACEA Biosciences Introduces a Multi-Option Configuration NovoCyte® Flow Cytometer
8. Pendant Biosciences Announces Acceptance into JLABS @ Toronto
9. Cancer and Immunotherapy Symposium Hosted by ACEA Biosciences Gathers Clinicians and Scientists From Around the World
10. TOMA Biosciences Releases the COMPASS Tumor Profiling System
11. Kindred Biosciences to Present at 2017 Jefferies Animal Health Summit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/9/2017)... ... October 09, 2017 , ... The Giving ... marijuana products targeting the needs of consumers who are incorporating medical marijuana into ... in Phoenix, Arizona. , As operators of two successful Valley dispensaries, The Giving ...
(Date:10/7/2017)... ... October 06, 2017 , ... ... applications consulting for microscopy and surface analysis, Nanoscience Instruments is now expanding ... offers a broad range of contract analysis services for advanced applications. Services ...
(Date:10/7/2017)... , Oct. 6, 2017  The 2017 ... of three scientists, Jacques Dubochet, Joachim Frank ... developments in cryo-electron microscopy (cryo-EM) have ... within the structural biology community. The winners worked ... can now routinely produce highly resolved, three-dimensional images ...
(Date:10/6/2017)... ... October 06, 2017 , ... On Tuesday, ... webinar on INSIGhT, the first-ever adaptive clinical trial for glioblastoma (GBM). The featured ... event is free and open to the public, but registration is required. , ...
Breaking Biology Technology:
(Date:10/4/2017)... 2017  GCE Solutions, a global clinical research organization (CRO), announces ... solution on October 4, 2017. Shadow is designed to assist medical ... policy 0070 of the European Medicines Agency (EMA) in meeting the ... ... ...
(Date:7/20/2017)... DAL ) customers now can use fingerprints instead of their ... (DCA). ... launches biometrics to board aircraft at Reagan Washington National Airport ... Delta,s biometric boarding pass experience that launched in May at ... process to allow eligible Delta SkyMiles Members who are enrolled in CLEAR ...
(Date:6/14/2017)... , June 15, 2017  IBM (NYSE: IBM ) is ... tech event dedicated to developing collaboration between startups and global ... June 15-17. During the event, nine startups will showcase the ... in various industries. France ... international market, with a 30 percent increase in the number ...
Breaking Biology News(10 mins):